BICYCLE THERAPEUTICS PLC
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
BCYC$3.69-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Six Months Ended | ||||||
| · · June 30, | ||||||
| · 2025 · 2024 | ||||||
| Cash flows from operating activities: · · · · | ||||||
| Net loss | | $(139,706) | | $(66,375) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Share-based compensation expense | | 19,040 | | 18,546 | ||
| Depreciation and amortization | | 3,330 | | 3,298 | ||
| Non-cash interest | | | — | | | 211 |
| Deferred income tax benefit | | (1,647) | | | (877) | |
| Changes in operating assets and liabilities: | | | | | | |
| Accounts receivable | | — | | (232) | ||
| Research and development incentives receivable | | (20,781) | | (22,575) | ||
| Prepaid expenses and other assets | | (8,571) | | (8,783) | ||
| Operating lease right‑of‑use assets | | 2,235 | | 2,187 | ||
| Accounts payable | | 1,080 | | (6,354) | ||
| Accrued expenses and other current liabilities | | 972 | | (3,626) | ||
| Operating lease liabilities | | (2,656) | | (2,382) | ||
| Deferred revenue | | (12,452) | | (28,671) | ||
| Other long-term liabilities | | — | | 137 | ||
| Net cash used in operating activities | | (159,156) | | (115,496) | ||
| Cash flows from investing activities: | | | ||||
| Purchases of property and equipment | | (1,102) | | (432) | ||
| Net cash used in investing activities | | (1,102) | | (432) | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from the issuance of ADSs and non-voting ordinary shares, net of issuance costs | | | — | | | 545,106 |
| Proceeds from the exercise of share options and settlement of restricted share units | | | 3 | | | 6,371 |
| Payments of finance lease obligations | | | (89) | | | — |
| Net cash (used in) provided by financing activities | | (86) | | 551,477 | ||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | | 2,275 | | (608) | ||
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (158,069) | | 434,941 | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 880,067 | | 526,970 | ||
| Cash, cash equivalents and restricted cash at end of period | | $721,998 | | $961,911 | ||
| Reconciliation of cash, cash equivalents and restricted cash | | | | | | |
| Cash and cash equivalents | | $721,451 | | $961,364 | ||
| Restricted cash in prepaid expenses and other current assets, and other assets, respectively | | | 547 | | | 547 |
| Total cash, cash equivalents and restricted cash | | $721,998 | | $961,911 | ||
| Supplemental disclosure of cash flow information | | | ||||
| Cash paid for interest on debt | | $— | | $1,146 | ||
| Cash paid for interest on finance lease obligations | | $44 | | $— | ||
| Cash (received from) paid for income taxes | | $(1,121) | | $792 | ||
| Equity issuance costs included in accounts payable and accrued expenses | | $— | | $979 | ||
| Cash paid for amounts included in the measurement of operating lease liabilities | | $2,956 | | $2,874 | ||
| Changes in purchases of property and equipment in accounts payable and accrued expenses | | $271 | | $26 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.